Diagnostic biomolecules and combination therapy for pre-eclampsia.

Jingqi Qi, Bingbing Wu, Xiuying Chen, Wei Wei, Xudong Yao

Reproductive biology and endocrinology : RB&E 2022 Sep 06

filter terms:

Pre-eclampsia (PE), associated with placental malperfusion, is the primary reason for maternal and perinatal mortality and morbidity that can cause vascular endothelial injury and multi-organ injury. Despite considerable research efforts, no pharmaceutical has been shown to stop disease progression. If women precisely diagnosed with PE can achieve treatment at early gestation, the maternal and fetal outcomes can be maximally optimized by expectant management. Current diagnostic approaches applying maternal characteristics or biophysical markers, including blood test, urine analysis and biophysical profile, possess limitations in the precise diagnosis of PE. Biochemical factor research associated with PE development has generated ambitious diagnostic targets based on PE pathogenesis and dissecting molecular phenotypes. This review focuses on current developments in biochemical prediction of PE and the corresponding interventions to ameliorate disease progression, aiming to provide references for clinical diagnoses and treatments. © 2022. The Author(s).

Citation

Jingqi Qi, Bingbing Wu, Xiuying Chen, Wei Wei, Xudong Yao. Diagnostic biomolecules and combination therapy for pre-eclampsia. Reproductive biology and endocrinology : RB&E. 2022 Sep 06;20(1):136